OUI Q2 2020 Update
OUI's momentum continues to build even under lockdown in a COVID-defying quarter.
OUI's momentum continues to build even under lockdown in a COVID-defying quarter.
Welcome to the Oxford University Innovation Q1 2020 update. OUI is now a month into its status as a virtual company with the entire office working from home, but we remain very much open for business. Below you’ll find all the usual updates from OUI and news from our spinouts, as well as an update on how Oxford is responding to the ongoing crisis.
Developing a pipeline of small molecule therapeutics for patients with immunological and genetic disorders.
Leading angel networks in Oxford merge to catalyse early-stage tech investment in the Oxford Cluster.
Y Combinator startup Prolific announces $1.2M seed round with participation from Pioneer Fund and prominent Silicon Valley Angel investors.
Oxford spinout developing novel therapeutics based on deep expertise in immune cell regulation.
LAB10x launched and AI@Oxford on the horizon in another active quarter for the Oxford Innovation Ecosystem.
Osage University Partners and Oxford University Innovation sign MoU on investment into Oxford University spinouts.
LAB10x aims to accelerate the commercialisation of the next generation of digital therapeutics and data-driven drug discovery from clinical artificial intelligence research and digital health innovations at Oxford University
Nightstar's supermassive acquisition leads on an active quarter for the Oxford University innovation community.